Wegovy Reduces BMI In Kids With Obesity As Young As 6
AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

In the phase III STEP Young trial, children ages 6 to 11 with obesity who received weekly semaglutide had a 13.5% mean BMI reduction at week 68, while the placebo group’s mean BMI rose 2.7%. The results, presented at ObesityWeek and published in the New England Journal of Medicine, also showed slower height gain with semaglutide; the treatment is not described in the report as approved for this age group.

A phase III trial found that weekly semaglutide was associated with a lower body mass index (BMI) in children ages 6 to 11 with obesity than placebo, according to results presented at ObesityWeek on November 16, 2026. At week 68, mean BMI had fallen 13.5% in the semaglutide group and risen 2.7% in the placebo group; the findings were also published in the New England Journal of Medicine. The results add evidence about a potential medicine-based treatment for younger children, but do not establish approval for this age group.

Before you orderOffer from Amazon

Get workout gear delivered free with Prime

  • Fast, free delivery on millions of items
  • Prime Video, Amazon Music and more included
  • Member-only deals all year
Start your free Prime trial Free trial for eligible customers · Cancel anytime
As an affiliate, we earn on qualifying purchases.

The STEP Young trial enrolled 167 children at 48 sites in nine countries. Participants were randomly assigned in a 2-to-1 ratio to weekly semaglutide or placebo for 104 weeks, and all received lifestyle counseling. The trial’s primary outcome showed an estimated 16.2-percentage-point difference in mean BMI change between the groups at week 68 (95% confidence interval, 19.4 to 12.9 percentage points lower with semaglutide; P<0.001).

At week 104, mean BMI change was down 9.4% with semaglutide and up 8.4% with placebo, a between-group difference of 17.8 percentage points. By week 68, 38% of children receiving semaglutide had a BMI below the obesity threshold for their age and sex, compared with 2% receiving placebo. At week 104, the figures were 33% and 2%. These proportions describe trial participants, not an expected result for every child.

The report said gastrointestinal events were the most frequent adverse effects. Through week 111, vomiting occurred in 70% versus 29% of the semaglutide and placebo groups, diarrhea in 62% versus 35%, and nausea in 58% versus 24%. Events were mostly described as mild to moderate and transient, with rates peaking during the 16-week dose-escalation period.

At a glance
reportWhen: Results presented November 16, 2026; tr…
The developmentResults from a phase III trial found substantially lower BMI in children ages 6 to 11 who received semaglutide than in those given placebo.

Potential Treatment for Younger Children

For children younger than 12, treatment options have generally centered on lifestyle support. The trial’s BMI findings could inform future decisions about whether medicines such as semaglutide have a role for children with obesity, particularly those with severe obesity or related health problems. The study does not by itself establish a change in clinical guidance or regulatory approval.

The findings also include a trade-off that families and clinicians will need to weigh: height gain was lower in the semaglutide group. Median height gain was 5.7 cm versus 7.8 cm at week 68, and 8.8 cm versus 12.1 cm at week 104. Researchers reported similar bone age, bone mineral density and pubertal progression between groups, but the height difference makes continued growth monitoring relevant if the treatment is considered for children.

Products Worth Considering

Philips Sonicare 7300 Rechargeable Electric Toothbrush with 3 Brush Heads, Black

Philips Sonicare 7300 Rechargeable Electric Toothbrush with 3 Brush Heads, Black

As an affiliate, we earn on qualifying purchases.

How STEP Young Was Conducted

Semaglutide, sold as Wegovy, is a GLP-1 medicine. The source report says it is approved for adolescents ages 12 and older with obesity; younger children have had fewer medication options, with lifestyle modifications forming the main approach in many cases. The report also notes that liraglutide, another GLP-1 medicine, is approved in the European Union for children ages 6 and older.

The trial ran from July 2023 to July 2026 and included children with a mean age of 10. More than half had at least one obesity-related complication. All received lifestyle counseling alongside their assigned treatment. The maximum weekly dose depended on baseline weight: 2.4 mg for children weighing more than 132 pounds and 1.7 mg for those weighing 99 to 132 pounds. After the 104-week treatment period, participants had a seven-week off-treatment washout.

“What we cannot capture with the numbers is the transformation that occurred in these visits. You would walk into the room and the child and their family just felt so different. These children were thriving.”

— Ania Jastreboff, MD, PhD, Yale School of Medicine, a trial researcher

Growth and Long-Term Safety Questions

The trial establishes BMI and adverse-event results over its treatment and follow-up period, but longer-term outcomes remain unknown. The source report highlights concern about effects of potent weight-loss medicines on linear growth and lean muscle development in children who have not reached puberty. In a subgroup of 50 assessed with scans, the semaglutide group had a greater reduction in fat-mass percentage and a greater increase in lean soft-tissue percentage than placebo; that subgroup result does not settle the broader growth question.

Researchers suggested slower height velocity might reflect normalization of BMI, noting that children with obesity can have faster growth before puberty. That is an interpretation, not a confirmed explanation. The available report does not establish whether the height difference persists after treatment or affects adult height. It also does not provide evidence that all children with obesity would have the same balance of benefits and risks. Some secondary cardiometabolic measures favored semaglutide, but they were not adjusted for multiple comparisons, and the prediabetes findings were exploratory.

Regulatory Review and Follow-Up

The findings were presented at ObesityWeek and published in the New England Journal of Medicine. The source report does not say that regulators have approved semaglutide for children under 12 or specify a regulatory decision date. Any future decision about use in this age group would need to account for the trial results, including the observed height-growth difference and the need for longer-term safety information.

Further follow-up will be needed to clarify whether BMI changes are sustained after medication stops and how treatment relates to growth and health over time. For now, the trial supports a measurable difference in BMI during treatment, while questions about longer-term effects and use in routine care remain open.

Key Questions

What did the STEP Young trial find?

At week 68, mean BMI fell 13.5% with semaglutide and rose 2.7% with placebo among children ages 6 to 11 with obesity. At week 104, mean BMI change was down 9.4% and up 8.4%, respectively.

Does the report say Wegovy is approved for children under 12?

No. The source report says semaglutide is approved for adolescents ages 12 and older with obesity. It does not report approval for children ages 6 to 11.

What side effects were reported?

Gastrointestinal events were most common. Through week 111, vomiting was reported in 70% of the semaglutide group and 29% of the placebo group; diarrhea and nausea were also more frequent with semaglutide.

Did semaglutide affect height gain?

Median height gain was lower in the semaglutide group at both week 68 and week 104. Researchers reported similar bone age, bone mineral density and pubertal progression between groups, but the longer-term meaning of the height difference is not established.

How many children took part?

The trial randomized 167 children: 112 to semaglutide and 55 to placebo. All participants also received lifestyle counseling.

Source: medpagetoday.com

Wellness content on this site is informational and not a substitute for professional medical guidance.
You May Also Like

Nutrition Strategies to Fuel Endurance Runs

You can transform your endurance runs with the right nutrition strategies—discover how to optimize your performance and recovery like never before.

Prostate Cancer Foundation Of Australia Surges In Global Coverage

The Prostate Cancer Foundation of Australia is experiencing a surge in international coverage, highlighting increased global interest in prostate cancer awareness and research.

Gut Training: Tolerating Gels and Drinks

When it comes to gut training for endurance events, understanding how to tolerate gels and drinks can make all the difference in your performance.

How to Choose Compact Home Rowing Machines

Learn how to select and set up a compact home rowing machine with this step-by-step guide for beginners and experienced users alike.